The budget impact of implementing atrial fibrillation-screening in European countriesShow others and affiliations
2024 (English)In: European Heart Journal, Supplement, ISSN 1520-765X, E-ISSN 1554-2815, Vol. 26, no Supplement_4, p. iv19-iv32Article in journal (Refereed) Published
Abstract [en]
A budget impact analysis estimates the short-term difference between the cost of the current treatment strategy and a new treatment strategy, in this case to implement population screening for atrial fibrillation (AF). The aim of this study is to estimate the financial impact of implementing population-based AF-screening of 75-year-olds compared with the current setting of no screening from a healthcare payer perspective in eight European countries. The net budget impact of AF-screening was estimated in country-specific settings for Denmark, Germany, Ireland, Italy, Netherlands, Serbia, Spain, and Sweden. Country-specific parameters were used to allow for variations in healthcare systems and to reflect the healthcare sector in the country of interest. Similar results can be seen in all countries AF-screening incurs savings of stroke-related costs since AF treatment reduces the number of strokes. However, the increased number of detected AF and higher drug acquisition will increase the drug costs as well as the costs of physician- and control visits. The net budget impact per invited varied from 10 in Ireland to 122 in the Netherlands. The results showed the increased costs of implementing AF-screening were mainly driven by increased drug costs and screening costs. In conclusion, across Europe, though the initial cost of screening and more frequent use of oral anti-coagulants will increase the healthcare payers' costs, introducing population screening for AF will result in savings of stroke-related costs.
Place, publisher, year, edition, pages
Oxford University Press (OUP) , 2024. Vol. 26, no Supplement_4, p. iv19-iv32
Keywords [en]
Anticoagulation; Atrial fibrillation; Budget impact analysis; ECG monitoring; Screening; Stroke prevention
National Category
Cardiology and Cardiovascular Disease
Identifiers
URN: urn:nbn:se:liu:diva-206244DOI: 10.1093/eurheartjsupp/suae076ISI: 001281979200004PubMedID: 39099577Scopus ID: 2-s2.0-85200264776OAI: oai:DiVA.org:liu-206244DiVA, id: diva2:1888606
Funder
EU, European Research Council
Note
Funding Agencies|This work has received funding from the European Union's Horizon 2020 research and innovation programme under the grant agreement No 847770 (AFFECT-EU). Data from the LOOP Study was used and LOOP was supported by Innovation Fund Denmark [grant number 12-1352259], The Research Foundation for the Capital Region of Denmark, The Danish Heart Foundation [grant number 11-04-R83-A3363-22625], Aalborg University Talent Management Program, Arvid Nilssons Fond, Skibsreder Per Henriksen, Rog Hustrus Fond, the European Union's Horizon 2020 program [grant number 847770 to the AFFECT-EU consortium], Laege Sophus Carl Emil Friis og hustru Olga Doris Friis' Legat, and an unrestricted grant from Medtronic. R.B.S. has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme under the grant agreement No 648131, from the European Union's Horizon 2020 research and innovation programme under the grant agreement No 847770 (AFFECT-EU) and German Center for Cardiovascular Research (DZHK e.V.) (81Z1710103 and 81Z0710114); German Ministry of Research and Education (BMBF 01ZX1408A) and ERACoSysMed3 (031L0239). Wolfgang Seefried project funding German Heart Foundation. From the European Union's Horizon Europe research and innovation programme under the grant agreement No. 101095480 (HYPERMAKER) DAS:Data available on request.
2024-08-132024-08-132025-02-10